Technology areas: Biotechnology & Pharmaceuticals • Computing & Software
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
The Translational Genomics Research Institute has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 5 examiners and 5 art units, indicating a fully distributed docket across distinct examination channels.
RAO, PADMAJA S is the busiest examiner, with 1 pending matter. No examiner has multiple reported matters, so counsel should emphasize coordinated deadline management and consistent portfolio positions while adapting each response to its separate examination setting.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| Multi-statute (no §101) | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
| JOHANSEN, PETER N. | 1 | 59.6% | +24.4% |
| PHAM, TUAN A | 1 | 83.6% | +27.0% |
| VAN DRUFF, SYDNEY | 1 | 55.3% | +32.0% |
| NEAGU, IRINA | 1 | 46.7% | +57.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18111875 | Methods of Profiling Mass Spectral Data Using Neural Networks | PHAM, TUAN A | 98d overdue |
| 17438155 | TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS | NEAGU, IRINA | 28d |
| 18699189 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | RAO, PADMAJA S | — |
| 18551356 | METHODS AND COMPOUNDS FOR NEOANTIGEN VACCINES | JOHANSEN, PETER N. | — |
| 17922315 | NEOANTIGEN-INFORMED TUMOR-INFILTRATING LYMPHOCYTE CANCER IMMUNOTHERAPY | VAN DRUFF, SYDNEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18111875 | Methods of Profiling Mass Spectral Data Using Neural Networks | PHAM, TUAN A | 98d overdue |
| 17438155 | TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS | NEAGU, IRINA | 28d |
| 18699189 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | RAO, PADMAJA S | — |
| 18551356 | METHODS AND COMPOUNDS FOR NEOANTIGEN VACCINES | JOHANSEN, PETER N. | — |
| 17922315 | NEOANTIGEN-INFORMED TUMOR-INFILTRATING LYMPHOCYTE CANCER IMMUNOTHERAPY | VAN DRUFF, SYDNEY | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1644 | 1 |
| 2163 | 1 |
| 1643 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18699189 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | RAO, PADMAJA S | 1627 | §103§112 | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18551356 | METHODS AND COMPOUNDS FOR NEOANTIGEN VACCINES | JOHANSEN, PETER N. | 1644 | §102§103 | Non-Final OA | — | Pending | Sep 19, 2023 |
| 18111875 | Methods of Profiling Mass Spectral Data Using Neural Networks | PHAM, TUAN A | 2163 | §101§103Other | Final Rejection | 98d overdue | Pending | Feb 20, 2023 |
| 17922315 | NEOANTIGEN-INFORMED TUMOR-INFILTRATING LYMPHOCYTE CANCER IMMUNOTHERAPY | VAN DRUFF, SYDNEY | 1643 | §102§103§112 | Final Rejection | — | Pending | Oct 28, 2022 |
| 17438155 | TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS | NEAGU, IRINA | 1629 | §103§112 | Final Rejection | 28d | Pending | Sep 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Translational Genomics Research Institute has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Padmaja S Rao has the most, with 1 of The Translational Genomics Research Institute's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
